---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042466"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-09-14T10:15:26+00:00"
generated_at: "2026-09-14T10:20:10.933984+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lipocine initiates BLOOM Phase 3 of LPCN 1154 for postpartum depression

## Summary
- BLOOM to enroll ~120 patients with severe PPD; first dosing expected early Q4 2026.
- Prior Phase 3 missed primary endpoint; post hoc analysis excluded one site with ~40% undetectable drug.
- No treatment-related severe/serious AEs or excessive sedation in prior Phase 3.
- Company has $23.3M cash (6/30/26); expects ~$1M/month cash use during study.
- Study incorporates FDA feedback and strengthened site quality controls.

## SEC filing metadata
- accession: 0001493152-26-042466
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-09-14T10:15:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226042466/0001493152-26-042466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226042466/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042466
- JSON: https://secwatch.observer/filing/0001493152-26-042466.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.